Navigation Links
Hepatitis Rates Soar Among IV Drug Users, Study Finds

WEDNESDAY, July 27 (HealthDay News) -- About 10 million injection drug users worldwide have hepatitis C, and 1.3 million have hepatitis B, a new study reports.

Hepatitis can lead to cirrhosis, liver failure and liver cancer.

Researchers analyzed international data and found that rates of hepatitis C infection among injection drug users (IDUs) were 60 to 80 percent in 25 countries and greater than 80 percent in 12 other countries.

These countries included Spain (80 percent), Norway (76 percent), Germany (75 percent), France (74 percent), United States (73 percent), China (67 percent), Canada (64 percent), Italy (81 percent), Portugal (83 percent), Pakistan (84 percent), the Netherlands (86 percent), Thailand (90 percent) and Mexico (97 percent).

Lower rates were seen in New Zealand (52 percent), Australia (55 percent) and the United Kingdom (50 percent), the researchers noted.

The countries believed to have the largest number of IDUs infected with hepatitis C virus (HCV) are China (1.6 million), the United States (1.5 million) and Russia (1.3 million), the investigators found.

Rates of hepatitis B infection were 5 to 10 percent in 21 countries and more than 10 percent in 10 countries. The highest rates were in Vietnam (20 percent), Estonia (19 percent), Saudi Arabia (18 percent) and Taiwan (17 percent). The United Kingdom had the highest rate in Western Europe at 9 percent. The rate in the United States was 12 percent.

The study, released to coincide with World Hepatitis Day, is published online July 28 in The Lancet.

"The public-health response to blood-borne virus transmission in IDUs has mainly centered on HIV. Maintenance and strengthening of the response to HIV in IDUs remains crucial, but the significance of viral hepatitis needs to receive greater attention than it does at present," Paul Nelson, from the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney, and colleagues wrote.

"Efforts to prevent, treat, and reduce harms related to liver disease in IDUs are essential -- especially in situations in which HIV has successfully been prevented or managed -- because the large numbers of IDUs infected with HCV and significant morbidity resulting from this infection mean that the health and economic costs of HCV transmitted by injected drug use might be as high as (or higher than) those of HIV," the authors added.

"Nonetheless, HCV treatment is underused. Part of the reason for this neglect is the high cost, which will remain a substantial barrier to increasing of treatment coverage in low-resource settings until costs are reduced," the researchers concluded.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about viral hepatitis.

-- Robert Preidt

SOURCE: The Lancet, news release, July 27, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China
2. Hepatitis B vaccination for health care students lags behind recommendations
3. Hepatitis C is transmitted by unprotected sex between HIV-infected men
4. P7 protein resistance mutations identified; represent drug targets for hepatitis C virus
5. Stepped-up vaccine series for hepatitis B is effective during pregnancy
6. New Drug Effectively Treats Hepatitis C
7. NEJM study: New drug represents breakthrough in treatment of hepatitis C
8. Noninvasive liver tests may predict hepatitis C patient survival
9. Analysis finds mortality from all causes higher among hepatitis C-infected
10. Scientists create humanized mouse model for hepatitis C
11. Coffee drinking improves hepatitis C treatment response
Post Your Comments:
Related Image:
Hepatitis Rates Soar Among IV Drug Users, Study Finds
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... , ... November 26, 2015 ... ... platform for mental health and wellness consultation, has collaborated with Women’s Web ... address their reader’s queries on topics on mental and emotional well-being relationship, ...
(Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a ... , For traditional saunas, Finnleo is offering 20% off all Nordic ... uses only European Grade A Nordic White Spruce from sustainably grown trees. Because of ...
(Date:11/25/2015)... Rouge, LA (PRWEB) , ... November 25, 2015 , ... ... in the United States District Court of Connecticut on behalf of a home health ... behalf of all current or former home health care workers employed by Humana, Inc., ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... network, announced the release of a new cutting edge recovery program that has been ... working with drug- and alcohol-addicted individuals with the purpose to free addicts from the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: